Christopher C. Gallen

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA.

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC.

Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension.

Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA.